Physician profile
Deepthi Jayasekara
NPI 1366426306
$56,698.75
in general payments reported to CMS, 2019-2025
17 companies · $8,168 in 2025
The $8,168 reported for 2025 was more than what 92% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,571 · 2020: $4,560 · 2021: $4,209 · 2022: $3,830 · 2023: $20K · 2024: $9,818 · 2025: $8,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $28K · Food and Beverage: $4,468 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,250 · Honoraria: $1,785 · Travel and Lodging: $639 · Education: $76.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $28,310.00 |
| Food and Beverage | $4,467.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,250.00 |
| Honoraria | $1,785.00 |
| Travel and Lodging | $638.91 |
| Education | $76.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $30,358.21 | 2022-2025 | Fetroja |
| La Jolla Pharmaceutical Company | $6,478.43 | 2020-2025 | Xerava, Xacduro, Zevtera |
| Allergan, INC. | $5,759.38 | 2019-2020 | |
| Abbvie INC. | $5,261.62 | 2021-2025 | |
| Melinta Therapeutics, LLC | $2,548.59 | 2019-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Ferring Pharmaceuticals INC. | $1,843.62 | 2020-2023 | Rebyota |
| Gilead Sciences, INC. | $1,471.59 | 2019-2025 | Biktarvy, Veklury |
| Viiv Healthcare Company | $1,345.04 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $580.88 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Insmed, INC. | $463.53 | 2019-2025 | Arikayce, Brinsupri |
| Cumberland Pharmaceuticals, INC. | $400.36 | 2022-2023 | Vibativ |
| Paratek Pharmaceuticals, INC. | $66.15 | 2021-2025 | Nuzyra |
| Tetraphase Pharmaceuticals, INC. | $39.19 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $22.71 | 2020 | |
| Astellas Pharma US INC | $21.63 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $21.39 | 2023 | Trogarzo, Egrifta |
| Pfizer INC. | $16.43 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepthi Jayasekara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.